HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030

HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aims to enhance operations, corporate systems, and governance. The combined company is expanding its manufacturing and R&D, focusing on specialty drugs and targeting new international markets.